Biotica, NeuroVive deal

NeuroVive acquired a portfolio of cyclophilin inhibitors, technology platform assets and related IP from Biotica. NeuroVive said it plans to use the technology and IP to develop next-generation versions of its mitochondrial products for cardiovascular and neuroprotection indications. The partners did not disclose financial details. ...